I. Arslan et al. / Bioorg. Med. Chem. 21 (2013) 1279–1283
1283
3.2. Plant material
was concentrated by blowing with N2. The residue was dissolved in
1-(trimethylsilyl)-imidazole and pyridine (0.1 mL), and the solu-
tion was stirred at 60 °C for 5 min. After drying the solution with
a stream of N2, the residue was partitioned between H2O and
CH2Cl2 (1 ml, 1:1 v/v). The CH2Cl2 layer was analysed by GC using
an l-Chirasil-Val column (0.32 mm ꢁ 25 m). Temperatures of the
injector and detector were 200 °C for both. A temperature gradient
system was used for the oven, starting at 100 °C for 1 min and
The underground parts of the Gypsophila arrostii Guss. var. neb-
ulosa (Boiss. & Heldr.) Barkoudah were collected from Korkuteli
district, Antalya Province of the Turkey in May 2011, and identified
by one of the authors (A. Celik). A voucher specimen of the plants is
kept (ACG1-3) at the Herbarium of the Faculty of Science and Arts,
Pamukkale University.
increasing up to 180 °C at a rate of 5 °C/min. Retention time,
cose, (14.70 min), -galactose (13.77 min), -fucose (11.20 min),
xylose (10.96 min), -rhamnose (10.71 min). From each saponin
glucose, -galactose, -fucose, -xylose,
D-glu-
3.3. Extraction and isolation
D
D
D
-
-
L
D
Roots of Gypsophila arrostii var. nebulosa L. (350 g) were crushed
and powdered. The saponins were extracted by stirring the suspen-
sion in 90% methanol (5 L) at room temperature. The MeOH solu-
tion was evaporated at 100 mbar, 40 °C. The remaining syrup
was kept at 4 °C for 24 h. The suspension was then filtered to re-
move water-insoluble tannins and other insoluble compounds.
Thereafter, the solution was fractionated (10 ꢁ 50 mL) and kept
in the freezer. In order to hydrolyse crufts like water-soluble tan-
nins each 50 mL fraction was adjusted with 30 mM sodium
hydroxide to pH ꢂ11. The chemical degradation with NaOH re-
duced the matrix complexity of the plant raw extract which facil-
itated an increased separation efficiency of the Gypsophila saponins
by HPLC. The solution was swirled 24 h at 40 °C and filtered
D
D
D
L
-rhamnose were detected.
3.7. Cytotoxicity assay
The procedure for the cytotoxic assay was performed according
to the XTT reduction method.16 In this study, the cell line ECV-304
(human endothelial cell line) was used. In brief, the ECV-304 cells
were placed in a 96-well plate at a dencity of 2000 cells per well in
100
(FBS). Saporin (6 nM) with and without nebuloside A and B
(25 g/mL) was added and cells were incubated for 72 h. For the
analysis of cytotoxicity 50 L (1 mg/mL) XTT containing 8 g/mL
lL moedified Eagles’s medium with 15% fetal bovine serum
l
l
l
phenazine methosulphate, was added to each well and cells were
incubated for 3 h at 37 °C. The absorbance of the produced forma-
zan was measured at 580 nm.
through a Nalgene™ Disposable Filterware (0.45 lm). To remove
the low molecular compounds the solution was dialyzed (MWCO
1000) against distilled water and finally freeze dried. A pre-puri-
fied saponin mixture (ꢂ300 mg) was obtained. After dissolving in
20% methanol, the saponins (0.5 mL, 40 mg) were subjected to an
Acknowledgments
UltraSep ES PHARM RP18E (7
l
m, 250 ꢁ 8 mm) column. Elution
The author thanks Stefan Böttger for skilful assistance during
purification process. This research was financially supported by
the Research Fund of the Pamukkale University. Project number
is 2009FBE017.
was performed with a gradient of methanol (A) trifluoroacetic acid
in water (0.01%) (B) starting with 20% A to 70% A over 60 min. The
flow rate was 1.5 mL/min. The separated saponins, nebuloside A
(10 mg, tR = 42.3 min), nebuloside
B
(11 mg, tR = 46.5 min),
1
(5 mg, tR = 42.3 min), (12 mg, tR = 42.3 min) and
2
3
(15 mg,
Supplementary data
tR = 42.3 min) were collected and analysed by ESI-TOF-MS. Finally
methanol was evaporated at 100 mbar, 40 °C and the saponins
were freeze dried.
Supplementary data associated with this article can be found, in
3.4. Nebuloside A
References and notes
1. Weng, A.; Jenett-Siems, K.; Schmieder, P.; Bachran, D.; Bachran, C.; Görick, C.;
Thakur, M.; Fuchs, H.; Melzig, M. F. J. Chromatogr. B 2010, 878, 713.
2. Arslan, I.; Celik, A.; Chol, J. H. Fitoterapia 2012, 83, 699.
3. Hostettmann, K.; Marston, A. Saponins. In Chemistry and Pharmacology of
Natural Products; Phillipon, J. D., Ayres, D. C., Baxter, H., Eds.; Cambridge
University Press: Cambridge, 1995; pp 326–327.
4. Frechet, D.; Christ, B.; Sorbier, B. M.; Fischer, H.; Vuilhorgne, M. Phytochemistry
1991, 30, 927.
5. Tschesche, R.; Wulff, G. Fortschr. Chem. Org. Naturst. 1973, 3, 461.
6. Rochd, M.; Fons, F.; Chahlaoui, A.; Henry, M. Acta Bot. Gallica. 2004, 151, 285.
7. Bai, H.; Zhong, Y.; Xie, Y. Y.; Wang, Y. S.; Liu, L.; Zhou, L., et al Chem. Biodivers.
2007, 4, 955.
3.4.1. 3-O-b-
(1?3)]-b- -glucuronopyranosyl quillaic acid 28-O-b-
pyranosyl-(1?3)-[b- -xylopyranosyl-(1?3)-b- -xylopyranosyl-
(1?4)]- -rhamnopyranosyl-(1?2)-b- -fucopyranosyl ester
D
-Galactopyranosyl-(1?2)-[b-
D
-xylopyranosyl-
D
D
-gluco-
D
D
a
-L
D
(nebuloside A)
White amorphous powder; ½a D20
ꢃ
+0.27 (c 0.0025, distilled
water); ESI-TOF-MS (negative ion mode) [MꢀH]ꢀ at m/z
1671.6532. For 1H/13C NMR data, see Tables 1 and 2.
3.5. Nebuloside B
8. Morrissey, J. P.; Osbourn, A. E. Microbiol. Mol. Biol. Rev. 1999, 63, 708.
9. Balandrin, M. F. Commercial Utilization of Plant-Derived Saponins: An
Overview of Medicinal, Pharmaceutical and Industrial Application. In
Saponins Used in Traditional and Modern Medicine; Waller, G. R., Yamasaki, K.,
Eds.; Plenum Press: New York, 1996; pp 1–14.
10. Lacalle-Dubois, M. A.; Wagner, H. Bioactive Saponins from Plants: An Update In
Studies in Natural Products Chemistry Series; Atta-Ur-Rahman, Ed.; Elsevier
Science: Amsterdam, 2000; Vol. 21, pp 633–687.
11. Harmatha, H. Chemo-Ecological Role of Spirostanol Saponins in the Interaction
Between Plant and Insects. In Saponins in Food Feedstuffs and Medicinal Plants;
Olezsek, W., Marston, A., Eds.; Kluwer Academic Publishers: Dordrecht, The
Netherlands, 2000; pp 129–141.
3.5.1. 3-O-b-
(1?3)-b- -galactopyranosyl-(1?2)]-b-
gypsogenin 28-O-b- -glucopyranosyl-(1?3)-[b-
-xylopyranosyl-(1?4)]- -rhamno-
D
-Xylopyranosyl-(1?3)-[b-
D
-galactopyranosyl
-glucuronopyranosyl
-xylo-
D
D
D
D
pyranosyl-(1?3)-b-
pyranosyl-(1?2)-b-
D
a-L
D
-fucopyranosyl ester (nebuloside B)
White amorphous powder; ½a D20
ꢃ
+0.21 (c 0.0025, distilled
water); ESI-TOF-MS (negative ion mode) [MꢀH]ꢀ at m/z
1820.7986. For 1H/13C NMR data, see Tables 1 and 2.
12. Marciani, D. J. U.S. Patent 5,977,081; 11 Fevr 1999.
13. De Tommasi, N.; Piacente, S.; Simone, F.; Pizza, C. J. Nat. Prod. 1993, 56, 1669.
14. Jia, Z.; Koike, K.; Nikaido, T. J. Nat. Prod. 1995, 61, 1368.
15. Hebestreit, P.; Weng, A.; Bachran, C.; Fuchs, H.; Melzig, M. F. Toxicon 2006, 47,
330.
3.6. Acid hydrolysis
A solution (2 mg each) of compounds nebuloside A and B in 1 N
HCl (0.5 mL) was stirred at 80 °C for 4 h. After cooling, the solution
16. Scudiero, D.; Shoemaker, R.; Paull, K.; Monks, A.; Tierney, S.; Currens, D.; Boyd,
M. Cancer Res. 1987, 28, 4827.